In Vivo CRO Market By Type of Service (Toxicology Testing, Pharmacokinetics and Pharmacodynamics (PK/PD) Studies, Efficacy and Safety Testing, Others); By Application (Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Others); By End-User (Pharmaceutical Companies, Biotechnology Firms, Academic and Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

In Vivo CRO Market: Growth Trajectory and Industry Overview

The in vivo cro market was $5,198 million in 2024 and will reach $9,140 million by 2030 at a CAGR of 9.8%. Pharmaceutical R&D development, enhancing regulatory demands for drug approval, and an escalating number of chronic and infectious diseases are expanding the market and requiring faster drug development.

 

The In Vivo CRO market is an important segment of Research including the preclinical and clinical phases crucial for drug and biologic development for pharmaceutical and biotechnology industries. These organizations offer an Investigation of the level of poison mechanisms in the body, how the drug composes in the body, how it behaves once in the body, and how effective it is on living test animals.

 

In Vivo CRO Market: Key Drivers, Opportunities and Restraints

Growing Demand for Outsourced Research: Pharmaceutical companies outsource preclinical and clinical trials to CROs as they concentrate more on cutting expenses and shortening time to market. The use of in vivo models in drug efficacy and safety studies is evident. In 2023, outsourced R&D spent 40% of the pharmaceutical industry's total investments.

 

Rising Prevalence of Chronic Diseases: The increased prevalence of chronic diseases, including cancer, cardiovascular diseases, and diabetes worldwide, has boosted the demand for new therapeutic products. In vivo CROs are used in animal testing to assess new therapies. Example: The WHO has estimated that global incidence of cancer will rise by 47% by 2040 which underlines the requirement for faster rates of progress in drug discovery.

 

Stringent Regulatory Requirements: The FDA and EMA require exhaustive in vivo preclinical examinations for drug safety and efficacy before clinical trials. These requirements raise the use of CROs for specialized Research. In 2024, new regulatory policies for animal model studies were issued, increasing the demand for CROs.

 

In Vivo CRO Market Opportunities: Innovations and Emerging Prospects

Advancements in Personalized Medicine: Precision Medicine is a growing trend of target treatments and precise drugs, opening up prospects for in vivo CROs/CDTs that focus on customized preclinical models. For example, CROs are uniquely building patient-derived xenograft (PDX) models for testing targeted therapy in oncology.

 

The emergence of Biologics and Biosimilars: Biologics and biosimilar drug developers are raising the need for in vivo pharmacokinetic and immunogenicity studies, where CROs offer expertise. The biologics market is growing at a rate of 12%, raising the need for in vivo experiments.

 

In Vivo CRO Market Restraints: Challenges Impacting Growth

Ethical Concerns and Alternatives: Ethical issues related to testing on animals and the shift towards non-animal test methods, including organ-on-chip, challenge the in vivo CRO industry. Example: European countries are stepping towards limiting animal testing and endorsing various models instead.

 

High Costs of Specialized Studies: Advanced in Vivo experiments on genetically modified animals or short-term chronic toxicity testing can often be expensive for small to medium biotechnology businesses.

 

In Vivo CRO Market Segmentation: Services, Applications, End-Users, and Regions

By Type of Service

• Toxicology Testing

• Pharmacokinetics and Pharmacodynamics (PK/PD) Studies

• Efficacy and Safety Testing

• Others

 

By Application

• Oncology

• Cardiovascular Diseases

• Infectious Diseases

• Neurological Disorders

• Others

 

By End-User

• Pharmaceutical Companies

• Biotechnology Firms

• Academic and Research Institutions

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

In Vivo CRO Market: Key Segment Insights Across Services, Applications, and End-Users

Leading segment: By Type of Service

Toxicology testing dominated the market in 2024, with a 35% revenue share among all forms of testing services. Toxicology studies are indispensable in revealing hazards and meeting authorities' requirements. Example: Long-term toxicity testing constitutes the most critical element of the preclinical phase, especially in oncology products.

Leading Segment: By Application

The oncology segment dominated the market with 40% of applications globally due to the growing burden of cancer and the growing pipeline of oncology drugs. In 2024, 1200 Oncology drugs were in the development stage globally and required in vivo testing.

Leading Segment: By Region

The pharmaceutical companies segment dominates the market because these organizations obtain CRO services for preclinical and clinical Research.

North America

In 2024, North America had the highest value market share, 45% of worldwide sales, due to the developed pharmaceutical market, high Research and development expenditures, and authorized legislation. The U.S. had 75% of North American revenue, boosted by the growth of oncology drug pipelines.

 

In Vivo CRO Market Competitive Landscape: Leading Players and Strategic Insights

• Charles River Laboratories: A global leader offering comprehensive in vivo services, including toxicology and pharmacology studies.

• Covance (Labcorp): Renowned for its end-to-end drug development services, with a strong focus on oncology.

• Envigo: Specializes in animal model development and toxicology testing.

• Taconic Biosciences: Provides genetically engineered mouse and rat models for preclinical studies.

• ICON plc: Offers integrated preclinical and clinical CRO services across therapeutic areas.

• WuXi AppTec: A leading provider of in vivo pharmacology and toxicology services with a strong presence in Asia.

• Eurofins Scientific: Focuses on regulatory toxicology and PK/PD studies.

• MPI Research: Known for its expertise in long-term toxicology and safety studies.

 

In Vivo CRO Market Report Coverage

Report Attribute	Details
Forecast Period	2023 – 2030
Market Size Value in 2023	USD 5.2 billion
Revenue Forecast in 2030	USD 9.1 billion
Overall Growth Rate	CAGR of 9.8% (2024 – 2030)
Base Year for Estimation	2022
Historical Data	2017 – 2021
Unit	USD Billion, CAGR
Segmentation	By Type of Service, By Application, By End-User, By Region
Key Services	Toxicology Testing, PK/PD Studies, Efficacy and Safety Testing, Others
Key Applications	Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Others
Key End-Users	Pharmaceutical Companies, Biotechnology Firms, Academic and Research Institutions
Geographical Regions	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Market Drivers	Rising R&D, regulatory demands, chronic and infectious disease prevalence, drug development speed
Market Opportunities	Personalized medicine, biologics, PDX models, biologics research, and biosimilars
Market Restraints	Ethical concerns, high study costs, non-animal models
Key Players	Charles River Laboratories, Covance, Envigo, Taconic Biosciences, ICON plc, WuXi AppTec, Eurofins Scientific, MPI Research

 

Future Outlook

The In Vivo CRO will expand rapidly over the years due to innovation in precision medicine, the escalating use of outsourcing, and the growing complexity of developing new drugs. Developing trends include augmented application of artificial intelligence and machine learning to improve study design, use of 3D bioprinting for other models, and increased prefabrication capabilities of CRO in developing worlds.

In conclusion, by 2030, in vivo CROs will be the key industry players offering solutions to meet the industry's dynamic changes. Industry players who have ventured into technology and geographical expansion will reap the rewards with unfolding opportunities.